# Rhythm Pharmaceuticals Expects to Dose First Phase III Patients in January

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/48205
Published: 2026-11-04T04:02:07.000Z
Updated: 2026-11-04T04:02:07.000Z
Section: Business

> The company committed $350 million to a royalty buy-down. CEO David Meeker cited $92 million in third-quarter revenue and called the U.S. launch an “excellent start.”

Rhythm Pharmaceuticals expects to begin dosing the first patients in January in a Phase III trial of bivamelagon for HO. The company also committed $350 million to a royalty buy-down.

Chairman, President and CEO David Meeker cited third-quarter revenue of $92 million and described the U.S. launch as an “excellent start.”